Insider Transactions in Q1 2025 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
623
-15.33%
|
$92,827
$149.29 P/Share
|
|
Feb 03
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,179
+22.48%
|
-
|
|
Jan 31
2025
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,740
-4.46%
|
$264,480
$152.89 P/Share
|
|
Jan 31
2025
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,740
+8.03%
|
-
|
|
Jan 31
2025
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,457
-4.31%
|
$221,464
$152.8 P/Share
|
|
Jan 31
2025
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,769
+7.57%
|
-
|
|
Jan 31
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,707
-0.52%
|
$411,464
$152.92 P/Share
|
|
Jan 31
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,141
+0.98%
|
-
|
|
Jan 31
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
126
-0.8%
|
$19,152
$152.97 P/Share
|
|
Jan 31
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
238
+1.49%
|
-
|
|
Jan 31
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
422
-12.76%
|
$64,566
$153.05 P/Share
|
|
Jan 31
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
801
+19.49%
|
-
|
|
Jan 31
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,541
-1.11%
|
$234,232
$152.87 P/Share
|
|
Jan 31
2025
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,927
+2.07%
|
-
|
|
Jan 31
2025
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,250
-2.97%
|
$190,000
$152.91 P/Share
|
|
Jan 31
2025
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,373
+5.33%
|
-
|
|
Jan 31
2025
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,104
-44.64%
|
$167,808
$152.94 P/Share
|
|
Jan 31
2025
|
David W. Boyer Chief Corp. Affairs Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,096
+45.87%
|
-
|
|
Jan 31
2025
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,207
-2.8%
|
$183,464
$152.94 P/Share
|
|
Jan 31
2025
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,294
+5.05%
|
-
|
|
Jan 31
2025
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,283
-3.78%
|
$195,016
$152.87 P/Share
|
|
Jan 31
2025
|
Matt Abernethy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,436
+6.69%
|
-
|
|
Jan 27
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
146,105
-22.11%
|
$21,769,645
$149.46 P/Share
|
|
Jan 27
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
146,105
+18.11%
|
$4,675,360
$32.99 P/Share
|
|
Jan 15
2025
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
65,000
-17.1%
|
$9,165,000
$141.5 P/Share
|
|
Jan 15
2025
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+13.43%
|
$2,080,000
$32.99 P/Share
|